Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 7/20 | 1.00 |
| ▸ | GSK3B | P49841 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | PIM1 | P11309 | 6/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.50 |
| ▸ | ATR | Q13535 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20189784 | 0.83 | GSK3B (1.00) | GSK3AGSK3BMAPTPIM1 | |
| SCHEMBL16703970 | 0.78 | GSK3A (0.67) | GSK3AGSK3BMAPTPIM1PIM3 | |
| SCHEMBL18107516 | 0.76 | GSK3A (0.66) | GSK3AGSK3BMAPTPIM1PIM3 | |
| SCHEMBL20189783 | 0.75 | GSK3A (0.60) | GSK3AGSK3BMAPTPIM1PIM3 | |
| SCHEMBL16703296 | 0.74 | GSK3B (0.67) | GSK3AGSK3BMAPTPIM1PIM3 | |
| SCHEMBL20189546 | 0.73 | GSK3A (0.58) | GSK3AGSK3BMAPTPIM1PIM3 | |
| SCHEMBL16704121 | 0.73 | GSK3B (1.00) | GSK3AGSK3BMAPT | |
| SCHEMBL20199477 | 0.73 | GSK3A (1.00) | GSK3AGSK3BMAPT | |
| SCHEMBL16704175 | 0.73 | GSK3B (1.00) | GSK3AGSK3BMAPT | |
| SCHEMBL20205105 | 0.72 | GSK3B (0.69) | GSK3AGSK3BMAPTPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544613-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3544613-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10752609-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752609-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-25 | — | — | US | disclosed |
| CN-110545817-A | GSK-3 inhibitors | SQUIBB BRISTOL MYERS COMPANY | 2019-12-06 | — | — | CN | disclosed |
| US-20190315714-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315714-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| EP-3544613-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018098412-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098412-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315714-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885MAPT 90/4885 |
| US-10752609-B2 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885MAPT 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.